Related Experiment Video

Updated: Jun 4, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation

Tatsuhiro Shibata1, Akiko Kokubu, Masashi Miyamoto

  • 1Division of Cancer Genomics, National Cancer Center Research Institute, Tokyo, Japan. tashibat@ncc.go.jp

The American Journal of Pathology
|March 2, 2011
PubMed

Insights

Isocitrate dehydrogenase (IDH) mutations, particularly IDH1, were found in 10% of melanoma cases, often co-occurring with BRAF mutations. These IDH1 mutations may drive melanoma metastasis and tumor growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Melanoma is an aggressive skin cancer with limited advanced-stage treatment options.
  • Genetic profiling reveals melanoma's molecular heterogeneity and potential therapeutic targets.

Purpose of the Study:

  • To investigate the prevalence and role of isocitrate dehydrogenase (IDH) mutations in melanoma.
  • To understand how IDH mutations interact with other oncogenic drivers like BRAF and KIT.

Main Methods:

  • Screening of 142 primary nonepithelial tumors for IDH1/IDH2 mutations.
  • Co-mutation analysis with BRAF and KIT.
  • Assessment of cellular growth and pathway activation (MAPK, STAT3) in BRAF-mutated melanoma with IDH1 mutations.
  • Genome-wide gene expression profiling.

Main Results:

  • IDH1 or IDH2 mutations were identified in approximately 10% (4/39) of melanoma cases.
  • IDH mutations frequently coexisted with BRAF or KIT mutations.
  • All IDH1 mutations were found in metastatic melanoma lesions.
  • BRAF-mutated melanoma cells with mutant IDH1 exhibited increased growth and enhanced MAPK/STAT3 pathway activation.
  • Mutant IDH1 altered gene expression, upregulating growth regulators and downregulating tumor suppressors like RASSF1.

Conclusions:

  • IDH1 mutations are present in a subset of melanomas and may contribute to metastatic progression.
  • The interplay between IDH1 and other oncogenic mutations (e.g., BRAF) influences melanoma aggressiveness.
  • Mutant IDH1 impacts gene expression profiles, potentially driving carcinogenesis in melanoma.

More Related Videos

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model10:23

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model

Published on: November 13, 2012

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic cells are...